Vivo Opportunity reports USD 32,319 purchase of InMed common shares

• Vivo Opportunity disclosed open-market purchases of InMed Pharmaceuticals common shares at USD 1.55.
• Vivo Opportunity Fund Holdings reported beneficial ownership rising to 743,057 shares.
• Vivo Opportunity Cayman Fund reported beneficial ownership rising to 75,019 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. InMed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-078891), on July 16, 2026, and is solely responsible for the information contained therein.